The study published in JAMA Network Open indicates that patients on semaglutide (Ozempic) were 63% less likely to experience opioid overdoses compared to those on DPP-4 inhibitors.
Rong Xu emphasized the significance of the findings, stating that this is the first large-scale study linking semaglutide to opioid overdose reduction, highlighting its potential in addiction management.
As interest grows in the impact of weight-loss drugs on cravings, Novo is progressing with a trial focusing on alcohol consumption, indicating broader implications for addiction therapy.
The research followed medical records of patients over a year, revealing that those taking semaglutide had a substantially reduced overdose risk, particularly noteworthy in the context of opioid use disorder.
Collection
[
|
...
]